Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allarity Therapeutics Inc ALLR

Healthcare Biotechnology
Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. It has in-licensed the... see more

Recent & Breaking News (NDAQ:ALLR)

Did Allarity Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ALLR

ACCESS Newswire July 26, 2024

ALLR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm!

ACCESS Newswire July 26, 2024

Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting

GlobeNewswire July 26, 2024

Allarity Therapeutics, Inc. (ALLR) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates

ACCESS Newswire July 25, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLR

PR Newswire July 25, 2024

ALLR Investors Have The Opportunity To Join The Allarity Therapeutics, Inc. Securities Fraud Investigation With The Schall Law Firm

ACCESS Newswire July 25, 2024

ALLR ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Allarity Therapeutics, Inc.

ACCESS Newswire July 25, 2024

ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm!

ACCESS Newswire July 25, 2024

ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Business Wire July 24, 2024

Rosen Law Firm Encourages Allarity Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - ALLR

Business Wire July 24, 2024

Lost Money on Allarity Therapeutics, Inc.(ALLR)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

ACCESS Newswire July 24, 2024

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors

Business Wire July 24, 2024

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors

Business Wire July 24, 2024

Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares

GlobeNewswire July 24, 2024

The Law Offices of Frank R. Cruz Announces Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors

Business Wire July 23, 2024

Allarity Therapeutics Outlines Company's 2024 Progress and Objectives

GlobeNewswire July 22, 2024

Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance

GlobeNewswire June 27, 2024

Allarity Therapeutics' Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer

GlobeNewswire June 25, 2024

Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

GlobeNewswire May 20, 2024

Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances

GlobeNewswire May 14, 2024